ES2193259T3 - Uso de compuestos de aminoadamantano como inmunorreguladores. - Google Patents

Uso de compuestos de aminoadamantano como inmunorreguladores.

Info

Publication number
ES2193259T3
ES2193259T3 ES96930065T ES96930065T ES2193259T3 ES 2193259 T3 ES2193259 T3 ES 2193259T3 ES 96930065 T ES96930065 T ES 96930065T ES 96930065 T ES96930065 T ES 96930065T ES 2193259 T3 ES2193259 T3 ES 2193259T3
Authority
ES
Spain
Prior art keywords
compounds
immunor
aminoadamantan
regulators
aminoadamantane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96930065T
Other languages
English (en)
Inventor
Erich F Elstner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Application granted granted Critical
Publication of ES2193259T3 publication Critical patent/ES2193259T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PUEDEN UTILIZARSE COMPUESTOS DE AMINOADAMANTANO PARA LA REGULACION Y/O MODULACION DE LA ACTIVIDAD DE NEUTROFILOS ACTIVADOS PREVIAMENTE IN VIVO O IN VITRO. POR CONSIGUIENTE, UN INTERVALO DE CONCENTRACIONES BAJAS FUNCIONA COMO AUMENTADOR DE LA ACTIVIDAD, MIENTRAS QUE UN INTERVALO DE CONCENTRACIONES ELEVADAS FUNCIONA COMO REDUCTOR DE LA ACTIVIDAD.
ES96930065T 1995-08-25 1996-08-21 Uso de compuestos de aminoadamantano como inmunorreguladores. Expired - Lifetime ES2193259T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19531342A DE19531342B4 (de) 1995-08-25 1995-08-25 Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren

Publications (1)

Publication Number Publication Date
ES2193259T3 true ES2193259T3 (es) 2003-11-01

Family

ID=7770407

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96930065T Expired - Lifetime ES2193259T3 (es) 1995-08-25 1996-08-21 Uso de compuestos de aminoadamantano como inmunorreguladores.

Country Status (21)

Country Link
US (2) US6172116B1 (es)
EP (2) EP0845984B1 (es)
JP (1) JPH11512093A (es)
KR (1) KR100392986B1 (es)
CN (1) CN1282452C (es)
AT (1) ATE234083T1 (es)
AU (1) AU718219B2 (es)
CA (1) CA2230159C (es)
CZ (1) CZ299356B6 (es)
DE (3) DE19531342B4 (es)
DK (1) DK0845984T3 (es)
EE (1) EE04261B1 (es)
ES (1) ES2193259T3 (es)
GE (1) GEP19991779B (es)
IL (1) IL123394A (es)
MX (1) MX217078B (es)
NO (1) NO319153B1 (es)
RU (1) RU2219916C2 (es)
UA (1) UA57711C2 (es)
WO (1) WO1997007791A1 (es)
ZA (1) ZA967137B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146143A0 (en) * 1999-04-28 2002-07-25 Univ Kingston Compositions and methods for treating amyloidosis
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
WO2006011823A1 (fr) * 2004-06-24 2006-02-02 Akciju Sabiedriba 'olainfarm' Agent immunostimulateur et interférogène
CA2900876A1 (en) 2004-12-22 2006-08-17 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
CN103209957A (zh) * 2010-08-09 2013-07-17 盐野义制药株式会社 氨基金刚烷氨基甲酸酯衍生物的制备方法
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
AU2017302305A1 (en) 2016-07-27 2019-02-14 Corium, LLC. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
WO2018022817A1 (en) 2016-07-27 2018-02-01 Corium International, Inc. Donepezil transdermal delivery system
RU2764764C2 (ru) 2016-07-27 2022-01-21 Кориум Интернэшнл, Инк. Трансдермальные системы доставки мемантина
CA3086163A1 (en) 2017-12-20 2019-06-27 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450761A (en) * 1967-03-30 1969-06-17 Sun Oil Co 1-aminoethyldimethyladamantane
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen

Also Published As

Publication number Publication date
DE10399029I1 (de) 2004-01-08
CZ299356B6 (cs) 2008-07-02
DE19531342B4 (de) 2007-11-29
EP1293201A2 (en) 2003-03-19
ZA967137B (en) 1997-03-12
KR19990044096A (ko) 1999-06-25
DE69626650D1 (de) 2003-04-17
CN1198669A (zh) 1998-11-11
US6255348B1 (en) 2001-07-03
GEP19991779B (en) 1999-10-05
CA2230159C (en) 2008-02-26
DK0845984T3 (da) 2003-06-23
NO980793D0 (no) 1998-02-25
DE19531342A1 (de) 1997-02-27
US6172116B1 (en) 2001-01-09
EE9800057A (et) 1998-08-17
AU718219B2 (en) 2000-04-13
WO1997007791A1 (en) 1997-03-06
NO319153B1 (no) 2005-06-27
EP0845984A1 (en) 1998-06-10
MX217078B (es) 2003-10-22
JPH11512093A (ja) 1999-10-19
CZ52498A3 (cs) 1999-04-14
DE69626650T2 (de) 2003-12-18
KR100392986B1 (ko) 2003-11-17
EP1293201A3 (en) 2003-05-21
IL123394A0 (en) 1998-09-24
MX9801496A (es) 1998-05-31
EE04261B1 (et) 2004-04-15
CA2230159A1 (en) 1997-03-06
CN1282452C (zh) 2006-11-01
RU2219916C2 (ru) 2003-12-27
UA57711C2 (uk) 2003-07-15
IL123394A (en) 2004-07-25
AU6926396A (en) 1997-03-19
NO980793L (no) 1998-02-25
EP0845984B1 (en) 2003-03-12
ATE234083T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
RU94041950A (ru) Использование соединений ряда 3-аролоксипропиламинов в лечении недержания
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
ES2193259T3 (es) Uso de compuestos de aminoadamantano como inmunorreguladores.
ES2119826T3 (es) Derivados 2-oxoetilicos como inmunosupresores.
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
BR9708468A (pt) Tratamento de fotoferese de leucocitos.
ES2149305T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.
ES2080037T1 (es) Medicamento de uso topico con actividad cicatrizante.
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
JO1589B1 (en) Ketones (quaternary hydroimidazo (4.1) benzo-diazepine-2) anti-viral
DE68926972D1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische Anwendungen
FI860816A (fi) Menetelmä terapeuttisesti käyttökelpoisten polyprenyyliyhdisteiden valmistamiseksi
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
HUT46214A (en) Process for producing medical preparation suitable for treatment of peptic ulcer
NZ335057A (en) Pentaerythritol derivatives, their production and use and intermediates for their synthesis
ES2094757T3 (es) Un factor megacariocitopoyetico.
ATE145911T1 (de) Inositol-phosphat-analog als kalzium- antagonistische substanz
IT1223395B (it) Composti ad attivita' cardiovascolare
TH24203A (th) อนุพันธ์ของออพทิคัลลี แอคทีฟ เบนโซไชอีพิน การเตรียมและการใช้ประโยชน์ของสารเหล่านี้
ES2037825T3 (es) Uso farmaceutico de tioeteres aromaticos.
ITRM920516A1 (it) Composizione e suo uso per il trattamento terapeutico di affezioni dermatitiche, particolarmente la psoriasi.
ECSP993296A (es) Moduladores de ccr5
ECSP993298A (es) Moduladores de ccr5
TH50173A (th) การใช้ 1-ไฮดรอกซี-2-ไพริโดนสำหรับการบำบัดการติดเชื้อที่ผิวหนัง